The use of nanotechnology has the potential to revolutionize the detection and treatment of
cancer. Developments in protein engineering and materials science have led to the …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-
renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Cancer immunotherapy works by stimulating and strengthening the body's anti-tumor
immune response to eliminate cancer cells. Over the past few decades, immunotherapy has …

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Harnessing an antitumor immune response has been a fundamental strategy in cancer
immunotherapy. For over a century, efforts have primarily focused on amplifying immune …

Monoclonal antibodies (mAbs) have become one of the most important classes of
biopharmaceutical products, and they continue to dominate the universe of …